Orexo AB (ORX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orexo AB (ORX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10149
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure-induced pain; OX-CLI for respiratory tract diseases; and OX-MPI for inflammation. The company employs its proprietary drug delivery technologies in the development of these products. It also carries out the industrial-scale production of pharmaceutical products. Orexo works in collaboration with various pharmaceutical companies including, Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB (ORX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10
Orexo AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orexo AB, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexo Enters into Commercialization Agreement with inVentiv Health for Zubsolv 12
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 13
Licensing Agreements 14
Mundipharma International Enters into Licensing Agreement with Orexo 14
Equity Offering 15
Orexo Raises USD50 Million in Private Placement of Shares 15
Debt Offering 17
Orexo Raises USD76 Million in Public Offering of Bond 17
Asset Transactions 18
Gesynta Pharma Acquires OX-MPI Program from Orexo 18
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 19
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 20
ProStrakan Acquires Abstral From Orexo For US$85 Million 22
Acquisition 23
Orexo Divests Kibion 23
Orexo AB – Key Competitors 24
Orexo AB – Key Employees 25
Orexo AB – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Oct 25, 2018: Orexo: Interim Report Q3 2018 27
Jul 11, 2018: Orexo: Interim Report Q2 2018 29
Apr 26, 2018: Orexo – Interim Report Q1 2018 30
Jan 25, 2018: Orexo: Full Year Report Q4 2017 31
Oct 19, 2017: Orexo Interim Report Q3 2017 32
Jul 11, 2017: Orexo Interim Report Q2 2017 33
Apr 20, 2017: Orexo: Interim Report Q1 2017 40
Jan 26, 2017: Orexo: Full Year Report 2016 41
Corporate Communications 42
Oct 24, 2018: Orexo appoints Joseph DeFeo as new CFO 42
May 31, 2018: Orexo’s CFO resigns and will leave the company in November 2018 43
Government and Public Interest 44
Sep 05, 2017: Orexo, together with Malmo University, receives research grant 44
Other Significant Developments 45
Oct 01, 2018: Orexo internalizes contract Field force in the US to further strengthen the commercial organization 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Orexo AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10
Orexo AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orexo Enters into Commercialization Agreement with inVentiv Health for Zubsolv 12
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 13
Mundipharma International Enters into Licensing Agreement with Orexo 14
Orexo Raises USD50 Million in Private Placement of Shares 15
Orexo Raises USD76 Million in Public Offering of Bond 17
Gesynta Pharma Acquires OX-MPI Program from Orexo 18
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 19
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 20
ProStrakan Acquires Abstral From Orexo For US$85 Million 22
Orexo Divests Kibion 23
Orexo AB, Key Competitors 24
Orexo AB, Key Employees 25
Orexo AB, Subsidiaries 26

List of Figures
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Orexo AB (ORX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Icon Energy Ltd (ICN):石油・ガス:M&Aディール及び事業提携情報
    Summary Icon Energy Ltd (Icon Energy), formerly Icon Oil NL, is an oil and gas exploration and production company that acquires, explores, and develops oil and gas properties. The company's exploration tenements include ATP 855, PRL's 33-49, ATP 594, ATP 626, ATP 794, ATP 549 West, PEP 170, PEP 172, …
  • Park City Group Inc (PCYG):企業の財務・戦略的SWOT分析
    Summary Park City Group Inc (Park City) is a technology company that provides supply chain, merchandising and store level solutions. The company offers scan based trading, vendor managed inventory, DSD visibility and strategic analysis, distribution center procurement, store level replenishment, ent …
  • Bausch & Lomb Incorporated:企業のM&A・事業提携・投資動向
    Bausch & Lomb Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bausch & Lomb Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Falck Renewables SpA (FKR):企業の財務・戦略的SWOT分析
    Falck Renewables SpA (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Option Care Enterprises Inc:企業の戦略的SWOT分析
    Option Care Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • J D Wetherspoon plc:企業の戦略・SWOT・財務情報
    J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report Summary J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Banco Santander SA:企業の戦略・SWOT・財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MKB Private Banking:企業の戦略・SWOT・財務分析
    MKB Private Banking - Strategy, SWOT and Corporate Finance Report Summary MKB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Brii Biosciences:製薬・医療:M&Aディール及び事業提携情報
    Summary Brii Biosciences is an independent biotechnology company that focuses on developing and commercializing innovative medicines for infectious diseases, liver and lung diseases, and other chronic diseases. The company strives to advance breakthroughs in science and technology, and enable patien …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • Siemens AG (SIE):医療機器:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Velan Inc (VLN):企業の財務・戦略的SWOT分析
    Velan Inc (VLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Suburban Propane Partners LP (SPH):企業の財務・戦略的SWOT分析
    Summary Suburban Propane Partners LP (Suburban Propane) distributes and markets energy-related products. The company supplies propane, fuel oil and refined fuels, and markets natural gas and electricity in deregulated markets. It also provides installation and service of various types of whole-house …
  • Nippon Kayaku Co., Ltd.:戦略・SWOT・企業財務分析
    Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Kayaku Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Daikin Industries, Ltd.:企業の戦略・SWOT・財務分析
    Daikin Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daikin Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Andersons Inc (ANDE):企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • DigitalGlobe Inc:企業の戦略的SWOT分析
    DigitalGlobe Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Keyence Corp (6861):企業の財務・戦略的SWOT分析
    Keyence Corp (6861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • XTL Biopharmaceuticals Ltd (XTLB):企業の財務・戦略的SWOT分析
    Summary XTL Biopharmaceuticals Ltd (XTL) is a drug development company that focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company’s pipeline products include hCDR1 peptide and recombinant human erythropoietin …
  • Total SA (FP)-石油・ガス分野:企業M&A・提携分析
    Summary Total S.A. (Total) is an integrated global oil and gas company that produces, refines and markets oil, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distribution of petrole …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆